title: Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study.
abstract: OBJECTIVE
  Tissue polypeptide antigen (TPA) is a differentiation and proliferation tissue marker of epithelia. Increased serum levels were found in some patients with invasive bladder cancer. We present the results of a prospective study that evaluated the role of serum TPA (S-TPA) in bladder carcinoma.
  
  
  METHODS
  The series included 167 patients treated for invasive bladder cancer between 1989 and 1996. S-TPA concentrations were measured by radioimmunoassay before treatment, at the end of treatment, and during follow-up evaluation. The upper normal limit of the test was set at 80 UI/L.
  
  
  RESULTS
  With a specificity of 100%, the diagnostic sensitivity was 46%. Pretherapeutic S-TPA levels were significantly correlated with tumor stage (T2 v T3 and T4; P = .02), with nodal stage (N0 v N1 and N2; P = .00001), and with metastatic stage (M0 v M1; P = 10[-6]), but not with histologic grading (grade 1 and 2 v 3). In the subset of patients with normal pretherapeutic S-TPA levels, 95% had no residual disease at the end of treatment, compared with 53% of patients with initial elevated S-TPA (P = 10[-8]). Among patients who achieved a complete response, 27% experienced a relapse, with an increase of S-TPA in 72% of cases. The mean follow-up time was 20 +/- 17 months. For patients with normal pretherapeutic S-TPA levels, 3-year overall survival and disease-free survival rates were 76% and 67% respectively. These were 46% (P = .001) and 25% (P = 10[-7]), respectively, for patients with high pretherapeutic S-TPA. Multivariate analysis showed that S-TPA was an independent prognostic factor for survival (P = .03).
  
  
  CONCLUSIONS
  In invasive bladder cancer, S-TPA level is correlated with initial tumor stage. It is a valuable parameter for follow-up evaluation and appears to be a prognostic factor in multivariate analysis.
authors.affiliation: Department of Oncology-Radiation Therapy, Tenon Hospital, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Maulard-Durdux
authors.forename: M E
authors.initials: ME
authors.lastname: Toubert
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.forename: M
authors.initials: M
authors.lastname: Housset
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis*; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011933:Reagent Kits, Diagnostic; D016019:Survival Analysis; D019396:Tissue Polypeptide Antigen / Q000097:blood*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000276:immunology
chemical_list: D014408:Biomarkers, Tumor; D011933:Reagent Kits, Diagnostic; D019396:Tissue Polypeptide Antigen